<DOC>
	<DOC>NCT01716754</DOC>
	<brief_summary>This study assessed the effect on asthma control of different dose levels and regimens of QGE031 in asthma patients that are inadequately controlled with inhaled steroid and beta-2 agonist medication. Safety was assessed also. Comparison was to placebo and omalizumab. Information from this study was planned to support the design of future studies.</brief_summary>
	<brief_title>Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Key A diagnosis of allergic asthma , uncontrolled on current medication. History of at least 1 asthma exacerbation during the last 1 year Forced Expiratory Volume in one second (FEV1) of ≥ 40% and ≤ 80% of the predicted normal value; reversibility following administration of bronchodilator must also be demonstrated (historical positive reversibility or bronchoprovocation result can be used). Key Baseline IgE levels or body weight outside the omalizumab dosing table. Use of tobacco products within the previous 6 months (Social occasional smokers may be included). Recent asthma attack/exacerbation or asthma worsening/ respiratory infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>asthma</keyword>
	<keyword>asthma control</keyword>
	<keyword>allergy</keyword>
	<keyword>atopic</keyword>
	<keyword>IgE</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo</keyword>
	<keyword>omalizumab</keyword>
</DOC>